Drexel University College of Medicine Studying Pill to Prevent HIV in Couples Wanting to Conceive
PHILADELPHIA, PA (PRWEB) June 04, 2015 -- For couples wanting to conceive a child when one partner is HIV-positive, the options have previously been limited to expensive assisted reproductive technologies, such as in vitro fertilization, or risking HIV transmission through unprotected intercourse. Now researchers at Drexel University College of Medicine are studying patient response to a once daily pill that prevents the spread of HIV infection in couples who are trying to get pregnant.
The study, taking place in four cities (Philadelphia, Boston, Baltimore, and Chicago), is the first of its kind in the U.S. It will involve couples who have chosen to begin a method known as PrEP, which stands for Pre-Exposure Prophylaxis. The once-daily pill Truvada was approved by the FDA in 2012 for this indication. It contains two medicines (tenofovir and emtricitabine) which work to keep the virus from establishing a permanent infection when someone is exposed to HIV through sex or injection drug use. When taken consistently, PrEP has been shown to reduce the risk of HIV infection by up to 92%.
“We know from efficacy trials that pre-exposure prophylaxis is an option to minimize transmission, but we need to find out what factors make PrEP feasible and acceptable to couples, as well as identify other factors that impact levels of adherence,” said Erika Aaron, CRNP, an assistant professor in the Division of Infectious Diseases and HIV Medicine at Drexel University College of Medicine, where she oversees a family planning clinic and coordinates a prenatal clinic for HIV-positive pregnant women in Drexel Medicine’s HIV practice. Aaron is the principal investigator at the Philadelphia study site. Over the past two and a half years, she has helped 10 HIV-negative women with HIV-positive partners get pregnant via condomless intercourse while on PrEP. None have become infected with HIV and all have had healthy babies.
“People who have HIV desire to have children at similar rates as people who do not have HIV. Now that HIV is more of a chronic disease controlled by medications, and people are living normal lives, there are many couples who desire pregnancy,” said Aaron. “It is important that we let people who are at risk of getting HIV know that PrEP is an option and help them make informed decisions about such important life choices.”
This is an observational study, in which standard of care is provided and the successes are then observed. The woman who is HIV-negative is prescribed PrEP along with proper risk reduction counseling and clinical monitoring. The partner who is HIV-positive is on effective HIV medications. Once pregnancy is achieved, the woman can opt to continue PrEP, which is safe in pregnancy.
The study is expected to last one to two years. Drexel has already started enrolling participants at the Philadelphia site. Anyone interested in participating should call 215-762-6826.
About Drexel University College of Medicine
Drexel University College of Medicine has established some of the most highly innovative and rigorous academic programs available today, incorporating the University’s expertise in engineering and technology into traditional medical training. The College of Medicine is home to one of the nation’s leading centers for spinal cord research; one of the foremost centers for malaria study; and a highly regarded HIV/AIDS program with extensive NIH-funded research in prevention and therapeutic interventions. Drexel University College of Medicine has been designated a Vanguard National Center of Excellence in Women’s Health by the U.S. Department of Health & Human Services, and is highly respected in numerous other specialties including cardiology and the neurosciences. Visit http://www.drexelmed.edu for more information. Follow Drexel University College of Medicine on Facebook, YouTube,Twitter and Instagram.
Rachel Quimby, Drexel University College of Medicine, http://www.drexelmed.edu, +1 215.255.7328, [email protected]
Share this article